Overview
China precision oncology firm's Q4 revenue was stable year-over-year at RMB126.3 mln
Gross profit and gross margin rose, supported by lower costs and higher-margin mix
Net loss narrowed sharply on lower operating expenses from cost controls and headcount reduction
Outlook
Company did not provide specific guidance for future periods
Result Drivers
CENTRAL LAB GROWTH - Revenue from central laboratory business rose 12.1% on higher CanCatch test volumes
IN-HOSPITAL EXPANSION - In-hospital business revenue rose 17.3% due to increased sales volume from existing and new partner hospitals
PHARMA SERVICES DECLINE - Pharma R&D services revenue fell 27.7% due to decreased testing services for pharma customers from timing of lumpy projects
Company press release: ID:nGNX6VPFB4
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | RMB 126.30 mln | ||
Q4 Net Income | -RMB 15.40 mln | ||
Q4 Adjusted Gross Margin | 80.30% | ||
Q4 Gross Profit | RMB 98.60 mln | ||
Q4 Operating Expenses | RMB 110.60 mln |
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)